Genomic Markers and Personalized Medicine in Androgenetic Alopecia: A Comprehensive Review
Laura Vila-Vecilla, Valentina Russo, Gustavo Torres de Souza
This review offers a thorough examination of the genetic basis of androgenetic alopecia (AGA) and its implications for personalized treatment strategies. AGA, the leading cause of hair loss worldwide, predominantly results from the effects of the hormone dihydrotestosterone (DHT). Recent advancements in genomics have pinpointed critical single-nucleotide polymorphisms (SNPs) linked to AGA, particularly within genes related to androgen metabolism, prostaglandin signaling, and vasodilation.
The review consolidates contemporary research on these genetic markers, exploring their potential in guiding the development of tailored therapeutic approaches that could revolutionize AGA management.
Epidemiologic Study of Gene Distribution in Romanian and Brazilian Patients with Non-Cicatricial Alopecia
Gustavo Torres, Monica Păun, George Sorin Țiplica, Victor Mihail Cauni
Androgenetic alopecia (AGA) and alopecia areata (AA) are common forms of non-cicatricial alopecia with limited treatment options, impacting patient quality of life. Pharmacogenetic testing offers personalized treatment guidance by assessing genetic variations. This study evaluates and compares specific SNPs and genes related to AGA and AA in Romanian and Brazilian populations. Results highlight significant genetic differences and potential treatment implications, underscoring the importance of genetic analysis in optimizing therapeutic outcomes for alopecia patients.
Utilising SNP association analysis as a prospective approach for personalizing Androgenetic Alopecia treatment
Francès MP, Vila-Vecilla L, Valentina Russo, Polonini HC, de Souza GT
This study focuses on correlating the genetic mechanisms of Androgenetic alopecia (AGA) with molecular targets involved in the response to current treatment modalities. An anonymised database including 26,607 patients was subjected to analysis. The study establishes a preliminary association between eight specific SNPs and AGA. These genetic markers offer insights into the variability of therapeutic responses, thus underlining the importance of personalised treatment approaches.
Genetic variant panel allows predicting both obesity risk, and efficacy of procedures and diet in weight loss
Mera-Charria A, Nieto-Lopez F, Francès MP, Arbex PM, Vila-Vecilla L, Russo V, Vicente Silva CC, De Souza GT
Obesity is a multifactorial condition with a relevant genetic correlation. Recent advances in genomic research have identified several single nucleotide polymorphisms (SNPs) in genes such as FTO, MCM6, HLA, and MC4R, associated with obesity. This study aimed to evaluate the association of 102 SNPs with BMI and weight loss treatment response in a multi-ethnic population.
Responsible: Fagron Genomics, SLU, VAT: ES-B67076059, Addres in C/ de les Cosidores, 150, 08226, Terrassa, Barcelona (Spain), phone (+34) 933 801 157 and email info@fagrongenomics.com Purpose: Manage and respond to your requests for information and / or consultations, 2. Manage the delivery of the information you request from us and, where appropriate, provide offers of products and / or services of Fagron Genomics, SLU in which you have expressed interest, 3. Manage the subscription and forwarding of our newsletter and commercial communications. Legitimation: Consent of the interested party. Addressees: The data is not disclosed to third parties except in cases where there is a legal obligation. Rights: to obtain confirmation as to whether Fagron Genomics, SLU is processing your personal data, and therefore you have the right to access this data, rectify inaccurate data or request its deletion when it is no longer necessary.
Additional and detailed information can be found in the section on Privacy Policy.